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Abstract Tourette syndrome (TS) is a neurodevelopmental
disorder of unknown etiology characterized by spontaneous,
involuntary movements and vocalizations called tics. Once
thought to be rare, TS affects 0.3–1% of the population. Tics
can cause physical discomfort, emotional distress, social difficulties, and can interfere with education and desired activities. The pharmacologic treatment of TS is particularly
challenging, as currently the genetics, neurophysiology, and
neuropathology of this disorder are still largely unknown.
However, clinical experience gained from treating TS has
helped us better understand its pathogenesis and, as a result,
derive treatment options. The strongest data exist for the
antipsychotic agents, both typical and atypical, although their
use is often limited in children and adolescents due to their
side-effect profiles. There are agents in a variety of other
pharmacologic categories that have evidence for the treatment
of TS and whose side-effect profiles are more tolerable than
the antipsychotics; these include clonidine, guanfacine,
baclofen, topiramate, botulinum toxin A, tetrabenazine, and
deutetrabenazine. A number of new agents are being developed and tested as potential treatments for TS. These include
valbenazine, delta-9-tetrahydrocannabidiol, and ecopipam.
Additionally, there are agents with insufficient data for efficacy, as well as agents that have been shown to be ineffective.
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Those without sufficient data for efficacy include clonazepam,
ningdong granule, 5-ling granule, omega-3 fatty acids, and
n-acetylcysteine. The agents that have been shown to be
ineffective include pramipexole and metoclopramide. We will
review all of the established pharmacologic treatments, and
discuss those presently in development.
Key Points
While most of the data for treatment of Tourette
syndrome (TS) indicate that antipsychotic
medications, both typical and atypical, are most
effective, other medications (e.g., clonidine,
guanfacine, topiramate, baclofen, botulinum toxin A,
and tetrabenazine) are typically used first to avoid
the potential side effects of dopamine blockade.
Presently, there is no medication that has proven
efficacy for all individuals with TS. This is likely due
to the phenotypic variability of individuals with TS.
There are promising medications in development for
the treatment of TS that offer different mechanisms
of action from antipsychotic medications, but the
data to support their use are preliminary. Specifically,
there are preliminary data for two new vesicular
monoamine transporter-2 (VMAT2) inhibitors
(deutetrabenazine and valbenazine), cannabinoids, and
ecopipam (a novel D1 receptor antagonist).
There are also some preliminary data indicating
possible effectiveness of some complementary and
alternative medicine preparations for the treatment of
TS; specifically, omega-3 fatty acids,
n-acetylcysteine, ningdong granule, and 5-ling
granule.

34

1 Introduction
Tourette syndrome (TS) is a neurodevelopmental movement disorder typically associated with comorbid psychiatric conditions (attention deficit disorder [ADHD],
obsessive compulsive disorder [OCD], anxiety, and
depression), characterized by the presence of motor and
vocal tics. The epidemiology of tics and TS has been
evaluated by several studies in the past. In 2012, Knight
et al. performed a systematic review and meta-analysis of
the prevalence, incidence, and epidemiology of tics and
TS. They reported an overall prevalence of TS in children
of 0.77%, alpha: 95% CI 0.39–1.51, which translates to 7.7
per 1000 school-aged children [1].
TS is characterized by the presence of tics, which are
‘‘sudden, rapid, arrhythmic, recurrent and involuntary
movements and/or sounds that are indistinguishable from
spontaneous movements but occur misplaced in context
and time’’ [2]. Tics are also commonly preceded by a
premonitory sensation followed by a sensation of relief
after the tic is performed. The actual tic itself, though, is
under conscious control. This, then, changes tics from
involuntary to semi-involuntary movements or sounds. It is
worth noting though that conscious tic suppression often
leads to an increase in inner tension and discomfort [3].
Though tics are the sine qua non finding in TS, they are not
exclusive to this condition and may be seen in other
medical conditions (e.g., Huntington disease, viral
encephalitis, substance abuse). In fact, the Diagnostic and
Statistical Manual of Mental Disorders (DSM), fifth edition, lists six different tic disorders [4].
The DSM V has specific criteria listed to diagnose TS;
these include presence of tics before the age of 18 years.
The tics must be present for at least 1 year and include at
least two motor tics and one phonic tic throughout the
course of the disease. The different tics do not need to
present concurrently, but should have been present at some
point throughout the illness course [4].
Tics initially present between the ages of 4 and 8 years.
Their frequency and severity tends to increase and become
worse between the ages of 8 and 12 years, followed by a
gradual decrease. According to the European clinical
guidelines for Tourette syndrome and other tic disorders,
80% of patients who present with tics under the age of
10 years will experience a significant decrease in tic frequency and severity during adolescence and by age
18 years will no longer experience any impairment from
tics [2]. The remaining 20% of patients do not experience a
decrease in tics and some of these patients might also go on
to develop the most severe and debilitating forms of tics [2].
It is difficult to establish a standardized treatment model
for tics. This is due to the spontaneous variations of tics in

J. Quezada, K. A. Coffman

an individual over time and the variable impact a tic can
have on different individuals and their families. The presence of co-morbidities that are usually present with TS and
their variable severity is another challenging feature in the
treatment of tics. The current options for treatment of tics
and TS include behavioral interventions, pharmacological
interventions, and surgical interventions, with the latter
reserved for the most severe and debilitating cases. The
following article will focus on reviewing current pharmacological treatment options available for management of
tics and TS. There is compelling evidence to indicate that
non-pharmacologic therapy, specifically comprehensive
behavioral intervention for tic (CBIT), is highly effective
for the treatment of TS [5] and should be considered as the
first therapeutic option for patients with TS [6]. A critical
first step in the treatment of TS is ‘‘proper education of the
patients, family members, teachers, and other individuals
who interact with the patient about the broad range of
clinical features and variable course of the disorder’’ [7]. If
CBIT is not appropriate, is ineffective, or is unavailable,
pharmacotherapy should be considered. This manuscript
offers a comprehensive review of the available evidence to
recommend different medications and a treatment algorithm to help choose the medication best suited for each
patient based on available medical evidence. The algorithm
is included in pictorial form as Fig. 1.
We searched PubMed using the keywords ‘Tourette
syndrome’ or ‘tic disorder’, ‘treatment’, ‘pharmacological
treatment’, ‘medication treatment’, in humans without any
date or language limits applied to the search. This search
yielded 229 results. Single case reports were then excluded.
Only references that discussed the treatment of TS were
further analyzed and used for the creation of this review.
Specific additional searches were performed for treatments
that were recommended upon initial peer review of this
manuscript. Additionally, established treatment guidelines
for the pharmacologic treatment of TS from Canada and
Europe were included in our analysis of evidence for
efficacy as there are no established treatment guidelines
from the United States.

2 Indications for Pharmacological Treatment
It is generally accepted that transient tic disorders do not
cause significant impairment in day-to-day activities and
therefore do not require any pharmacological intervention
routinely. With regards to TS, however, it has been
demonstrated that scores for validated quality of life (QoL)
measures are low for these patients. It seems, though, that
the lower scores attained are not related to tics themselves,
but more so to the co-morbidities associated with TS and
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Fig. 1 Tourette syndrome treatment algorithm. Therapies follow a
progression that starts with the intervention that has no side effects
and concludes with the medications that can have the most severe side
effects. Medication selection should follow this progression. Note that
there is more than one medication category in each progressive line of
therapy, so more than one option is available in each tier.
Complimentary medications are available and have evidence for

their use as an add-on therapy and not as single agents. Alternative
medications are available and have some evidence for their efficacy,
but are not widely used and cannot yet be recommended. Drugs under
investigation show promise in the treatment of tics, but still need
further studies before their use can be recommended. VMAT2 vesicular monoamine transporter-2

peer victimization (teasing by other children because of
tics) [8]. Treatment for tics is therefore only required when
the tics themselves are causing social problems (e.g., bullying), emotional problems (e.g., low self-esteem, depression, anxiety), discomfort (e.g., physical pain or injuries) or
impair performance (e.g., academic or sleep disruption)
[9].
Behavioral interventions should be recommended as an
initial intervention. They are highly effective as demonstrated by the landmark placebo-controlled trial in 2010 by
Piacentini et al. and are free from pharmacologic side
effects [5]. If these interventions are not successful or not
feasible (e.g., lack of coverage by insurance, lack of certified therapists, unwillingness of patient to participate),
pharmacologic interventions can be pursued. When initiating a medication for treatment of tics, it is important to
bear in mind that these interventions may not completely
eliminate tics. On average, medications for tics can reduce
symptoms by about 25–50% [9]. This information should
be communicated with the patient and family members to
avoid disappointment and frustration. In clinical practice,
some patients may achieve complete or near complete
control of tics with medication therapy; however, this
should not be put forth as the expectation when initiating
pharmacotherapy.

3 Agents with Evidence of Efficacy
We will now discuss a variety of agents for which there is
sufficient evidence for efficacy in the treatment of TS.
These agents are presented in three categories: nondopaminergic agents, agents that act through blockade of
dopamine receptors, and agents that are vesicular
monoamine transporter-2 (VMAT2) inhibitors.
3.1 Non-dopaminergic Agents
There is evidence suggesting, based on the observation of
tic improvement with the use of dopaminergic blocking
agents, that abnormal dopaminergic signaling is involved
in the pathophysiology of tics. Abnormal dopaminergic
signaling does not, however, explain the close association
of TS with ADHD and OCD and other psychiatric comorbidities like anxiety, depression, and oppositional
defiant disorder. Noradrenergic and serotoninergic systems
appear to be involved in the pathophysiology of TS, yet
their exact role is still unclear [10]. The successful use of
non-dopaminergic medications for tic management along
with management of comorbidities in TS further supports
this notion.
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3.1.1 Alpha-2 Agonists
3.1.1.1 Clonidine Clonidine has been used for TS for
over 30 years. It is an a-2 adrenergic receptor agonist. Case
reports of its efficacy first appeared in the 1980s and initial
open-label trial evidence was contradictory. The controversy was deepened by randomized trials that showed
minimal to no improvement of tics with clonidine [11]. The
controversy was laid to rest after a large randomized control trial (RCT) was conducted in 2002 by the Tourette
Study Group. The trial included 136 children with TS and
ADHD who were randomized to receive clonidine alone or
methylphenidate alone or clonidine ? methylphenidate or
placebo. In this study, tic severity improved the most in the
clonidine ? methylphenidate group followed by the clonidine alone group and least improvement was seen in the
methylphenidate alone group followed by the placebo
group [12]. Another benefit of clonidine is its availability
as an oral preparation as well as a transdermal preparation.
A 2008 double-blind, placebo-controlled multicenter trial
of 437 patients using a clonidine adhesive patch versus
placebo revealed a significant improvement in the randomly assigned clonidine group compared with the clinical
control group [13]. Side effects commonly seen with
clonidine include sedation, bradycardia, orthostatic
hypotension, and dry mouth, as well as localized skin
irritation with the clonidine patch. Thanks to the preferable
side-effect profile and moderate quality of evidence of tic
reduction with clonidine, this medication was given a
strong recommendation by the Canadian guidelines for
evidence-based treatment of tic disorders with its use
applicable to most patients without reservations by the
physician [14]. Recommended starting dose is 0.05 mg per
day and titrate up slowly with a close monitoring of blood
pressure and heart rate to a therapeutic range of 0.1–0.3 mg
per day in adults and children, divided 3–4 times per day
[11, 14].
3.1.1.2 Guanfacine Guanfacine is another a-2 adrenergic
receptor agonist that has a moderate effect in tic reduction
and improving attention. The evidence in favor of use of
guanfacine for tic reduction comes from two open-label
studies [15, 16] and three RCTs [17–19]. Both of the openlabel studies showed an improvement in tic severity with
the use of guanfacine [15, 16]. All three RCTs compared
guanfacine with placebo. The first RCT evaluated 34
children with TS and ADHD who were randomized to
either receive guanfacine or placebo over an 8-week period. At the end of this period, patients on guanfacine had a
statistically significant reduction in their Yale Global Tic
Severity Scale (YGTSS). The patients in the placebo group
had no change in their score. The patients receiving
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guanfacine also had an improvement in their ADHD
symptoms [17]. The second RCT was of poor quality and
failed to show a difference between guanfacine and placebo [18]. The third RCT compared extended-release
guanfacine with placebo. Despite a reduction in the
YGTSS, it failed to show a clinically meaningful effect
size for tic reduction with the use of the extended-release
formulation (YGTSS total score declined from
26.25 ± 6.61 to 23.56 ± 6.42, p = 0.08) [t(15) = 1.84;
p = 0.08; effect size = 0.35] [19]. The main side effects of
guanfacine include fatigue, insomnia, irritability, lightheadedness, stomachache, and sleep disturbance. Like
clonidine, guanfacine had a strong recommendation with a
moderate level of evidence by the Canadian guidelines for
evidence-based treatment of tic disorders [14]. Dosing is
recommended to start at 0.5 mg per day and titrate to up to
4 mg per day [11, 14].
3.1.2 Baclofen
Baclofen is a GABAB receptor agonist that is commonly
used for the treatment of spasticity. The GABAergic
properties of baclofen were suggested to be helpful in tic
management after an open-label trial in 1999. A total of
264 patients aged 6–18 years were treated with an initial
dose of 10 mg per day with subsequent dose increases of
10 mg/week until desired tic suppression was achieved or
the patient developed side effects. The dose ranged
10–80 mg/day (mean 30 mg/day) for 4 weeks. Statistically
significant decreases were noted in motor and vocal
(p\0.02) tics as measured by the YGTSS, although further
data were not provided. Six patients experienced sedation
and drowsiness [20]. This trial, along with an RCT [21] of
10 children 8–14 years old randomized to either baclofen
or placebo that demonstrated a decrease in the YGTSS that
was not statistically significant, was included in the
Canadian guidelines for evidence-based treatment of tic
disorders. The recommendation was weak due to low
quality of evidence [14].
3.1.3 Topiramate
Topiramate is a broad-spectrum anticonvulsant that is
GABAergic, and blocks AMPA (a-amino-3-hydroxy-5methylisoxazole-4-propionic acid)/kainate receptors. To
date, there is only one randomized, double-blind, placebocontrolled trial of topiramate for the treatment of TS. This
10-week study of 29 subjects (pediatric and adult)
demonstrated a statistically significant reduction in YGTSS
total tic score [22]. Dose range was 25–200 mg/day. The
main side effects were headache and diarrhea.
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3.1.4 Botulinum Toxin A
Botulinum toxin (Botox) is a neurotoxic protein that inhibits acetylcholine release at the neuromuscular junction. It
is Food and Drug Administration (FDA) approved for the
treatment of migraine headache, blepharospasm, cervical
dystonia, and spasticity [23]. There is one randomized,
placebo-controlled trial for Botox in the treatment of TS. It
was a small study of only 20 patients, but it did demonstrate statistically significant reduction in tics [24]. Patients
did not feel that they had improvement, despite the results.
Weakness, not surprisingly, was the main side effect, and
no dosing guidelines were provided.
3.2 Dopaminergic Blockade
Dopamine blockade was demonstrated to be beneficial for
tic reduction in 1973 with the use of haloperidol (Haldol)
[10]. The hallmark clinical finding in TS is tics, which have
led some to classify it as a movement disorder, different
from hyperkinetic movement disorders [2]. This classification may lead one to believe that the pathological findings in TS should reside within the basal ganglia. Tics,
however, wax and wane, are influenced by a patient’s
emotional state, and can be temporarily suppressed [2].
These findings suggest that tics are not solely based on
basal ganglia pathology and likely involve the limbic system as well. Another interesting finding in tic disorders is
that the tics temporarily remit during periods of intense
attention, like playing an instrument or performing a task
[6]. These high-attention scenarios require engagement of
the cerebral cortex, which therefore implies that the cerebral cortex is also involved in the genesis of tics. The
circuitry that involves these structures (cortex, basal ganglia, and thalamus) has been termed the cortico-striatothalamo-cortico circuit (CSTC). ‘‘Three CSTC circuits are
potentially involved in GTS: the habitual behavioural circuit (the premotor cortex–putamen circuit), the goal-directed circuit (the ventral medial prefrontal cortex–caudate
nucleus circuit) and the emotion-related limbic circuit
(inputs from the hippocampus, amygdala, prefrontal cortex
and anterior cingulate gyrus to the ventral striatum)’’ [6].
Dopamine blocking agents have been postulated to help
control tics by blocking abnormal dopaminergic systems
within the aforementioned circuits. The beneficial effects
of dopamine, specifically D2 receptor, blockade have been
reported to provide up to 70% tic reduction, although it is
achieved at the cost of side effects derived from this
mechanism—medication-induced dyskinesias [25]. Other
important side effects may result from hyperprolactinemia
(galactorrhea, gynecomastia, irregular menses, and sexual
dysfunction) and alterations in cholinergic, serotonergic,
histaminergic, and alpha-adrenergic transmission, and
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thereby might lead to weight gain, drowsiness, and
excessive sedation [9, 11].
3.2.1 Typical Antipsychotics
3.2.1.1 Pimozide Pimozide is a dopamine receptor
blocker, but also acts as a calcium channel blocker. It
causes fewer medication-induced dyskinesias than
haloperidol, and also exhibits less sedative effects [11, 26].
A Cochrane review from 2009 evaluated six RCTs comparing pimozide with placebo alone, haloperidol alone,
placebo and haloperidol, and risperidone in the treatment
of tics. Pimozide was superior to placebo in three RCTs.
Compared with haloperidol, pimozide showed similar
efficacy in two RCTs and was inferior in one RCT. No
significant differences between pimozide and risperidone
were detected [27]. Pimozide has been associated with
cardiac arrhythmias and prolongation of QTc interval. A
2011 study compared the cardiovascular safety profile of
pimozide with that of aripiprazole and found that patients
taking pimozide developed lower blood pressure and a
prolongation of QTc interval, while patients on aripiprazole
showed an elevation in blood pressure and no changes in
QTc interval [28]. Pimozide is used at doses of 2–8 mg per
day given once daily, with a maximum of 10 mg/day [26].
Children C 2 years and adolescents initially receive
0.05 mg/kg/dose once daily, preferably at bedtime; dose
may be increased every third day if needed; maximum
daily dose is 0.2 mg/kg/day, not to exceed 10 mg/day [29].
Pimozide was approved by the FDA for use in patients with
TS in 1984 [30].
3.2.1.2 Haloperidol Haloperidol was the first medication
shown to be effective for tic management. Its potential
beneficial effects were first reported in a case report in a
patient who had undergone a frontal lobectomy and experienced a reduction of tics with use of haloperidol [31].
Haloperidol has been shown to be effective when compared with other typical neuroleptics and in placebo-controlled trials [29, 32–35]. It has been estimated that
haloperidol might achieve up to 91% tic reduction at
maximum dose [28]. These benefits are offset by the higher
incidence of adverse effects when compared with other
typical neuroleptics. Significantly, a 24-week, doubleblind, placebo-controlled, randomized, cross-over study
found that haloperidol did not have a significant effect on
tics, but did have a 3-fold increased risk of side effects
compared with pimozide [29]. Haloperidol is usually
started at 0.5 mg/day and carefully titrated upwards in
0.25- to 0.5-mg increments every 5–7 days until optimal tic
control is achieved. The typical dose range for treatment of
tics with haloperidol is 2–10 mg daily, although doses up
to 20 mg daily have been studied [33]. Due to its higher
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risk of side effects, haloperidol should only be used in
severely disabled patients who have failed other medications [29]. Haloperidol was the first medication approved
by the FDA for the treatment of adult patients with TS in
1969 and for children in 1978 [30].
3.2.1.3 Fluphenazine Fluphenazine is one of the oldest
typical antipsychotics that acts by blocking both D1 and D2
receptors [26]. A retrospective chart review from 2014
evaluated the treatment response of 268 patients over a
26-year period. Patients were started at an average age of
15.8 years and received the medication for an average of
2.6 years. Results showed that of the 268 patients, 211
(80.5%) had a moderate improvement of tics. The most
common side effects included drowsiness, fatigue, or both,
observed in 70 (26.1%) patients. There were no cases of
tardive dyskinesia (TD) [36]. An older placebo-controlled,
double-blind trial reportedly showed fluphenazine and trifluoperazine to be as effective as haloperidol but with
fewer side effects when used for tic suppression, mainly
TD [37]. Fluphenazine should be considered for treating
moderate to severe tics that are refractory to preferred
treatments. Fluphenazine is started at 0.5–1.0 mg daily and
slowly increased by 0.5- to 1.0-mg increments every
5–7 days to approximately 3 mg per day in children and up
to 10 mg per day in adults [14, 26].
3.2.2 Atypical Antipsychotics
Ten atypical antipsychotics are currently approved by the
FDA in the USA: risperidone, olanzapine, ziprasidone,
quetiapine, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, and clozapine. These medications were
developed in an effort to decrease the likelihood of medication-induced dyskinesias, while also providing a means
to control psychosis. Their safer side-effect profile, with
regards to medication-induced dyskinesia, has sparked the
use of atypical antipsychotics for other indications that are
not yet FDA approved, like mood disorders, other psychoses, autism spectrum disorder and tics [26].
Atypical antipsychotics are not without risk. Their sideeffect profile does include an increased risk of developing
metabolic abnormalities, type 2 diabetes mellitus, cardiovascular disease, weight gain, and endocrine abnormalities
like hyperprolactinemia. Patients on atypical antipsychotics
should undergo routine measurement of weight, BMI, waist
circumference, blood pressure, liver function tests, fasting
serum lipids, and glucose [26].
The European Society for the Study of Tourette Syndrome (ESSTS) distributed an online survey to 57 of its
active members in 18 different countries in 2012 in order to
determine their prescribing practices. They obtained a
response from 44 clinicians that showed that risperidone
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was the most commonly prescribed drug for treatment of
tics [38].
3.2.2.1 Aripiprazole Aripiprazole is a partial D2, D3,
and D4 receptor agonist, as well as a partial 5-HT1A and
5-HT2C receptor agonist. As a partial D2 receptor agonist,
it results in an overall decrease in D2 stimulation. It has
moderate affinity for histamine and alpha-adrenergic
receptors [26]. There are multiple placebo-controlled randomized trials supporting the use of aripiprazole for TS.
The first, published in 2013, was a 10-week trial of children
and adolescents and contained 61 subjects. It demonstrated
significant reduction in the mean total tic score on the
YGTSS of 15 compared with 9.6 for the placebo group
(p = 0.0196) [39]. The most recent was an 8-week study
published in 2017. This large study, which enrolled 133
children and adolescents, demonstrated significant reduction in tics on the YGTSS and critically demonstrated that
more than 65% of patients in the treatment groups had
‘very much improved’ or ‘much improved’ scores on the
Clinical Global Impression–Tourette’s Syndrome scale
[40]. Common side effects between these two studies were
sedation, somnolence, and weight gain [38, 39]. The
Canadian guidelines for the treatment of TS gave aripiprazole a weak recommendation due to the quality of data;
however, this recommendation predates the two large
placebo-controlled trials discussed above [14]. Aripiprazole was FDA approved for the treatment of TS in 2014
[41]. Recommended initial dose is 2 mg per day with a
maximum of 10 or 20 mg a day, depending on weight.
3.2.2.2 Risperidone Risperidone is the best examined
atypical antipsychotic for treatment of TS. Risperidone is a
5-HT2 receptor antagonist at low doses and functions as a
D2 antagonist at high doses. It also has moderate to high
affinity for a-2, D3, D4, and H1 receptors [26]. It has been
demonstrated to have similar or even better efficacy for tic
management when compared with pimozide [42, 43].
There are a total of five randomized, double-blind, control
trials that have demonstrated efficacy of risperidone for the
treatment of tics [42–46], yet the long-term side effects (of
which hyperprolactinemia due to tubero-infundibular D2
antagonism is the most impactful) may be significant
[9, 47]. In fact, the Canadian Guidelines for the EvidenceBased Treatment of Tic Disorders gave risperidone a weak
recommendation for tics in TS due to its risk–benefit profile as it requires monitoring of medication-induced dyskinesias and metabolic side effects [14]. Due to its diverse
effects on neurotransmission, risperidone may be useful for
treating co-morbid symptoms such as aggression or
obsessive–compulsive symptoms in children with TS,
though more evidence for treating psychiatric comorbidities in TS with risperidone is needed [26]. Doses are
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initiated at 0.25 mg daily and increased every 5–7 days as
indicated to approximately 0.25–4.0 mg daily [11, 14].
3.2.2.3 Olanzapine Olanzapine is characterized by its
high-affinity antagonism of D1, D2, D3, D4, 5-HT2A,
5-HT2C, H1, and muscarinic receptors [9]. The use of
olanzapine in TS is supported by three open-label studies,
one non-randomized, single-blind study with a 2-week
placebo run-in, and one non-randomized crossover study
comparing olanzapine with pimozide [48–52]. All of these
studies reported a decrease in tic severity with use of
olanzapine. While all three open-label studies reported a
decrease in tic severity and improvement in the YGTSS,
they all reported significant side effects due to sedation,
weight gain, and increased appetite [48, 50, 52].
Compared with other atypical antipsychotics, olanzapine
has greater 5HT2C than D2 antagonism, which may
explain the lower incidence of medication-induced dyskinesias [11]. Additionally, olanzapine does not appear to
block dopamine within the tubero-infundibular tract,
explaining the lower incidence of hyperprolactinemia than
with typical antipsychotic agents or risperidone [11].
Nevertheless, the metabolic side effects seen with olanzapine may limit its use [26]. Olanzapine causes the most
weight gain among second-generation antipsychotics, and
has been associated with increases in BMI and waist circumference, lipids, liver enzymes, and blood sugar [11].
Olanzapine is started at 2.5–5.0 mg daily and increased
every 5–7 days up to a maximum of 20 mg daily [11].
3.2.2.4 Ziprasidone There is minimal evidence to support the use of ziprasidone in TS. Its efficacy for reduction
of tics has been demonstrated in one randomized, doubleblind, placebo-controlled study in 28 children and adolescents [53] and one open-label study in 24 children and
adolescents [54]. It has low affinity for D2 receptors, high
affinity for 5HT2A, 5HT1A, and 5HT2C receptors, and
moderate affinity for M1 and H1 receptors. The use of
ziprasidone requires monitoring for medication-induced
dyskinesias and EKG for prolongation of QTc [14]. Unlike
other atypical antipsychotics, it does not seem to cause
significant weight gain. Side effects include somnolence,
sedation, and akathisia. Ziprasidone is started at 5–10 mg
daily and gradually increased every week to 10–40 mg
daily [14].
3.2.2.5 Quetiapine Quetiapine has moderate affinity for
5-HT1A, 5-HT2, D1, D2, and H1 receptors and has low
affinity for a-1 and a-2 adrenergic receptors. The evidence
for the use of quetiapine for tics in TS comes from two
open-label studies. One study involved 12 adults and did
not show a statistically significant reduction in tics after
12 weeks of treatment with a mean dose of 205.8 mg/day
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[55]. The other was an 8-week trial on 12 subjects with a
mean age of 11.4 ± 2.4 years. At the end of the 8-week
period, subjects had a statistically significant reduction in
the YGTSS [56]. Sedation and weight gain are the most
common reported side effects. Quetiapine can be initiated
at 12.5–25.0 mg daily and increased as tolerated and
indicated up to 300–400 mg daily [26].
3.2.2.6 Benzamides This class of drugs includes tiapride,
sulpiride, and amisulpride. In the German-speaking world,
benzamides such as tiapride and sulpiride are commonly
used as first-line agents to treat TS, particularly in children
and adolescents. None of these agents are available in the
US [11]. They are specific D2-blocking agents, yet in
contrast to the typical antipsychotics, they have little to no
antipsychotic effect.
Tiapride has been used for management of tics since
1970. It not only blocks the supersensitive D2 receptor in
the striatum, but it is also assumed that it has some 5HT3
and 5HT4 blocking capabilities [11]. The main adverse
reactions include drowsiness, transient hyperprolactinemia,
and weight gain [11]. In a double-blind, randomized, placebo-control, crossover study for tiapride, no adverse
reactions on the patient’s cognitive performance were
reported and the study found ‘‘good clinical antidyskinetic
properties’’ [57].
The positive effects of sulpiride on tic management have
also been reported on since 1970 [11]. In addition to these
effects, it has also been shown to have mild antipsychotic,
antidepressive, and anxiolytic effects [11]. Sulpiride is a
highly selective D2 receptor blocker with fewer medication-induced dyskinesias and vegetative side effects than
haloperidol. An open-label study in 2009 evaluated 189
children, with an average age of 8 years, after 6 weeks of
sulpiride treatment for tics. There was reported improvement of vocal and motor tics on this medication, with
sedation being reported as a side effect in 16.4% of participants [58]. Successful treatment of tics with amisulpiride has only been published in case reports [11].
3.3 Vesicular Monoamine Transporter-2 Inhibitors
The VMAT2 transports dopamine, norepinephrine, and
serotonin from synaptic vesicles to the synapse [59]. There
are currently three VMAT2 inhibitors with evidence for, or
studies being developed for, the treatment of TS (tetrabenazine, deutetrabenazine, valbenazine).
3.3.1 Tetrabenazine
Tetrabenazine is currently FDA approved for the treatment
of the chorea in Huntington disease. By inhibiting VMAT2,
it prevents translocation of neurotransmitter monoamines
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from the cytoplasm into synaptic vesicles. The data for the
use of tetrabenazine comes a from long-term, open-label
study by Jankovic et al. [60]. In this study of 10 individuals
with TS, who were treated for an average of 9.4 months,
four had marked improvement in tic control, and three had
mild improvement. All responders were children or teens.
Drowsiness was the most common side effect. There was
also a long-term, open-label prospective analysis of 120
subjects, both pediatric and adult, which demonstrated that
76% ‘‘improved on the clinical global impression of
change (CGI-C)’’. Unfortunately, 93% of the subjects in
this study were on other medications at the time [61]. To
date, there has not been a randomized placebo-controlled
trial of tetrabenazine [59]. The Canadian guidelines for the
treatment of TS give it a weak recommendation for ‘‘very
low-quality data’’ [14]. No clear dosing guidelines are
available.
3.3.2 Deutetrabenazine
Deutetrabenazine is an isotopic isomer of tetrabenazine
resulting from the replacement of the two methoxy groups
(–OCH3) with two trideuteromethoxy groups (–OCD3)
installed at the 9 and 10 positions. This increases the halflife and reduces side effects. Deutetrabenazine has
recently been FDA approved for the chorea from Huntington disease as well as tardive dyskinesia [62]. This
medication has been studied in a 6-week, open-label trial
of 12- to 18-year-old patients with TS. There was a
reduction in the mean YGTSS score of 11.2 on doses of
18–36 mg a day [61]. Side effects were fatigue, headache,
and irritability. No placebo-controlled studies have been
completed to date.
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the treatment of a myriad of neurologic disorders. Delta-9tetrahydrocannabinol (THC) acts as an agonist of the
cannabinoid receptor. There are placebo-controlled, randomized trials for the treatment of TS. The first was a
2-day, single-dose trial with a 4-week washout. There were
statistically significant reductions in both tics and OCD
behaviors [64]. The second trial was a sustained treatment
trial, 6 weeks in duration, of 24 subjects, with an escalating
dose schedule. It did demonstrate significant reduction in
tics, without significant side effects [65]. In both studies,
dronabinol was used and dosing was 5–10 mg a day. Curtis
et al., in a Cochrane Review article, concluded that currently there is not significant data to determine if it is
effective at this point for TS [66].
4.3 Clonazepam
Clonazepam is a benzodiazepine that has a long history in
the treatment of TS [67], yet no placebo-control trials have
been done [11]. There have been two single-blind comparison studies of clonazepam. The first study showed that
clonazepam was superior to clonidine for tic suppression
[68], and the second study, conducted by Merikangas et al.,
showed that patients with a high red blood cell to plasma
choline ratio responded better to clonazepam than to
haloperidol [69]. This is critical based on a prior observation of elevated red blood cell choline levels in patients
with TS [70]. There are no data on other benzodiazepines
except a case report about the therapeutic effect of lowdosage diazepam on facial tics in children [71]. As with all
benzodiazepines, the use of clonazepam is limited by tolerance and adverse reactions including sedation, short-term
memory problems, ataxia, and paradoxical disinhibition
[11].

4 Agents Without Sufficient Evidence of Efficacy

4.4 Dopamine D1 Receptor Antagonist

4.1 Valbenazine

Ecopipam is a selective D1/D5 antagonist that is being
studied for TS. Presently, there is one open-label, 8-week
study of 18 adults with TS. Subjects had a 5.2 decrease in
YGTSS total score during treatment. The main side effects
seen were sedation, fatigue, and insomnia [72]. There are
preliminary results available for the ongoing multicenter,
double-blind, placebo-controlled crossover trial of ecopipam in children and adolescents that were presented in a
poster at the 2017 Movement Disorders Society meeting by
Gilbert et al. [73]. This study enrolled 40 subjects aged
7–17 years. The preliminary data showed a statistically
significant reduction of YGTSS scores at both 2 and
4 weeks, with mild-to-moderate side effects, but no weight
gain, medication-induced side effects, EKG or laboratory
changes. This study has not been submitted for publication
at this point in time.

Valbenazine is a VMAT2 inhibitor, FDA approved for the
treatment of tardive dyskinesia, that is presently being
studied for the treatment of TS [63]. There are presently
three phase II trials of TS ongoing in the US. At time of
publication, none of these studies have published results.
Side effects have been sedation, anticholinergic effects,
and balance disorders.
4.2 Cannabinoids
4.2.1 Delta-9-tetrahydrocannabinol
Derivatives of the Cannabis sativa plant have recently
received extensive popular press and attention in the US for
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4.5 Complementary and Alternative Agents
4.5.1 Ningdong Granule
Ningdong granule (NDG) is a formulation of four different
plant species (Uncaria rhynchophylla (Miq.) Jacks, Gastrodia elata Blume, Ligusticum chuanxiong Hort, Glycyrrhiza uralensis), three animal products (Buthus
martensii, Scolopendra subspinipes mutilans, Haliotis
diversicolor), and dried human placenta [74]. NDG is
thought to modulate dopamine content and dopamine D2
receptor content in the striatum. This was demonstrated by
Zhang and Li by using two rat models in which concentrations of dopamine in the striatum were pharmacologically
altered by using apomorphine (Apo) to increase the dopamine concentration in the rat striatum and 3,30 -iminodipropionitrile (IDPN) to decrease the dopamine
concentration in the rat striatum. By using high-performance liquid chromatography, they demonstrated that
alterations in dopamine content in the striatum was corrected in both rat models after administration of NDG, while
no changes were seen with administration of haloperidol.
There have been two RCT to evaluate the efficacy of NDG
in treating tics. The first one was done in 2009 and compared
haloperidol plus NDG to haloperidol alone in children with
TS. At the end of their 24-week trial, they observed mean
difference between the two groups in their YGTSS score of
4.35 points with a 95% CI, p = 0.004 [75, 76]. The second
one, a 2010 RCT conducted by Zhao et al., compared NDG
with placebo over an 8-week period in children with TS
between the ages of 7 and 18 years. After 8 weeks of
treatment with NDG, subjects exhibited a 41.39% reduction
in the YGTSS global score from baseline, while the placebo
group showed a 10.79% reduction in YGTSS global score.
Regarding side effects, two subjects reported loss of appetite
and one experienced constipation in the NDG group,
p\0.001 [77].
4.5.2 5-Ling Granule
5-Ling granule (5-LGr) is a patented polyherbal product with
11 herbal materials (Radix Paeoniae Alba, Rhizoma Gastrodiae, Fructus Tribuli, Ramulus Uncariae cum Uncis,
Lucid Ganoderma, Caulis Polygoni Multiflori, Semen Ziziphi Spinosae, Fructus Schisandrae Chinensis, Fructus
Gardeniae, Rhizoma Arisaematis cum bile, Radix Scutellariae) [78]. Zheng et al. performed a double-blind RCT in
2016 comparing the efficacy and safety of 5-LGr with placebo and tiapride. This multisite trial was conducted from
January 2008 to November 2010 and prospectively recruited
patients from eight different hospitals in China. The patients
were between 5–18 years old and had to have a diagnosis of
TS for at least 1 year based on the fourth edition of the DSM
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(DSM-IV). All of the patients enrolled in this 8-week trial
showed improvement in their YGTSS. The global YGTSS
showed an average score improvement for placebo (baseline:
50, week 2: 44.4, week 8: 31.5), tiapride (baseline: 51.4,
week 2: 43.2, week 8: 21.2) and 5-LGr (baseline: 52.1, week
2: 44.2, week 8: 22.3). The most common adverse events
were ‘‘tiredness, reduced appetite and upper respiratory tract
infections’’, which were seen in 11.2% of placebo patients,
26% of tiapride patients, and 13.8% of 5-LGr patients [78].
4.5.3 Omega-3 Fatty Acids
Omega-3 fatty acids (O3FAs) are long-chain polyunsaturated fatty acids of 18–22 carbon atoms in chain length with
the first double bond between the third and fourth carbon
atoms (n-3). Docosahexaenoic acid (DHA: 22 carbon atoms
and 6 double bonds) and eicosapentaenoic acid (EPA: 20
carbon atoms and 5 double bonds) are main forms of O3FA
[79]. In 2012, Gabbay et al. conducted a 20-week, doubleblind trial comparing O3FA (DHA:EPA capsules at a ratio of
2:1) with placebo in children with TS assessing the effects of
O3FA on tic suppression by measuring changes in YGTSS
tic, global and impairment scores. Their subjects had to fulfill
the DSM-IV, Text Revision criteria for TD and have a
minimum YGTSS of 20. Patients with any other medical or
psychiatric disease were excluded and they did not exclude
patients with TS on concomitant psychotropic medication.
They enrolled 33 patients and had eight patients dropout
(three O3FA group and five placebo group). At the end of the
20-week period, there were no significant differences in
response rates between O3FA and placebo on the YGTSS tic
score (YGTSS tic score decrease of 5.2 ± 7.3 vs 3.6 ± 5.6 for
O3FA and control group, respectively). They did, however,
observe a decrease in the YGTSS global scores (31.7 ? 2.9
vs 40.9 ? 3.0), and a trend in favor of O3FA on the YGTSS
impairment scales (16.9 ? 2.1 vs 23.0 ? 2.2). O3FA are
unlikely to have any role in tic reduction, but might play a
role in helping with tic-related impairment and improvement
in wellbeing [79].
4.5.4 N-Acetylcysteine
N-Acetylcysteine (NAC) is an amino acid supplement that
has glutamate-modulating activity. NAC is converted to
cystine, a substrate for the glutamate/cystine antiporter
located on glial cells. The uptake of cystine by glia causes
glial release of glutamate into the extra synaptic space, where
it appears to stimulate inhibitory metabotropic glutamate
receptors on glutamatergic nerve terminals, and thereby
reduces the synaptic release of glutamate [80]. The glutamatergic system has been implicated in the pathogenesis of
TS, with reduced glutamate levels found post mortem in the
globus pallidus interna, globus pallidus externa, and
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substantia nigra pars reticulata in patients with TS compared
with controls [6]. In 2016, a randomized, double-blind,
placebo-controlled, add-on trial compared NAC with placebo in the treatment of tics in TS. Their primary goal was a
reduction in the YGTSS in patients with TS who were on a
stable medication regimen (no addition, discontinuation, or
dosing change in medications that have potential effects on
the central nervous system (such as antidepressants, naltrexone, lithium, psychostimulants, anxiolytics, or antipsychotics) in the previous 4 weeks prior to trial initiation).
They enrolled 31 patients and had two patients drop out, one
in the treatment group and one in the placebo group. Patients
were randomized at a 1:1 ratio to receive either NAC or
placebo as an add-on treatment. At the end of their 12-week
trial, they observed no benefit with the use of NAC as an addon treatment for children and adolescents with TS on any
primary or secondary clinical measures [81].

5 Agents that are Ineffective
5.1 Pramipexole
Pramipexole is a dopamine agonist that acts on D2, D3, and
D4 receptors. In 2012, a randomized, multicenter, placebocontrolled trial compared pramipexole with placebo for tics
in TS. Their primary outcome was a change in the YGTSS
tic score. They were able to recruit 63 patients and completed a 6-week trial. At the end of the trial, there were no
significant differences in the adjusted mean change in the
total tic score of the YGTSS for patients treated with
pramipexole and placebo [82].
5.2 Metoclopramide
Metoclopramide is classified as a neuroleptic medication
with poor efficacy as an antipsychotic agent [83]. It is
commonly used as an antiemetic and is the most common
cause of drug-induced dyskinesias. A 2005 RCT in 27
patients aged 7–18 years demonstrated a 39% reduction in
the YGTSS in the metoclopramide group, compared with a
13% reduction in the YGTSS in the control group [84].
This study provided weak evidence for the use of this
medication for tics, and given the experience and potential
for tardive dyskinesia and parkinsonism, it is not recommended for the treatment of tics in TS [14].

6 Conclusions
The treatment of TS has been slow to evolve over the last
almost 50 years, since the approval of haloperidol by the
FDA in 1969. For the majority of that time period, a large
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proportion of the medications that underwent investigation
for the treatment of TS had a salient feature in common,
they are D2 receptor antagonists. These medications, while
proven to be effective, have the potential for serious side
effects, either due to their D2 receptor antagonism, or their
modulation of serotonin receptors, in the case of the
atypical antipsychotics. The side effect profile of these
medications, as delineated above, have relegated most of
these medications to third- or fourth-line agents in the
treatment of TS, despite their proven efficacy.
Aripiprazole is the first FDA-approved medication for
the treatment of TS that does not have significant D2
antagonist effects. It also has significantly lower risk of
hyperprolactinemia and weight gain than many of the other
newer atypical antipsychotics [26].
For many practitioners, the alpha-2 agonists, clonidine
and guanfacine, have become first-line pharmacologic
treatment for TS given their favorable side-effect profile
compared with the antipsychotics. This is in spite of the
fact that the level of evidence for their effectiveness is less
than some of the antipsychotics and they are not FDA
approved for the treatment of TS. This practice is reinforced by the Canadian treatment guidelines for the treatment of TS [14], whereas the European guidelines indicate
that risperidone should be the first choice for pharmacotherapy [11].
In recent years, there has been increased interest in nonneuroleptic, non-noradrenergic options to control tics.
Topiramate, a broad-spectrum anticonvulsant, has promising data regarding efficacy, but more studies are needed to
confirm that it is truly effective. Ecopipam, the D1 receptor
antagonist, has promising preliminary data, including a
placebo-controlled trial supporting its effectiveness, but
peer-reviewed published manuscripts are not available at
the present time to assess side effects of this novel agent.
There is great interest in the VMAT2 inhibitors, especially given the recent FDA approval of valbenazine, and
the preliminary, open-label data for deutetrabenzine. The
interest in these agents arises from both patients and
practitioners looking for safe and effective treatment
options for TS. With the significant cost of tetrabenazine
and valbenazine treatment in the US market, these medications, if effective, may have little impact on a large scale
due to their expense.
In the US, there is presently a ubiquitous desire for the
use of cannabinoid medications for many neurologic and
non-neurologic disorders. The public plea for pharmacologic options in this category of potential pharmacologic
agents stems, in large part, from the fact that they are
derived from a natural source—the Cannabis sativa plant.
Many patients and families, in response to the numerous
stories of medications being removed from the market due
to emerging side effects, as well as a desire to take a more
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naturopathic path in the treatment of disease, are incredibly
interested in ‘natural’ treatments for their health concerns.
There are very promising data for the use of cannabinoids,
specifically THC, for the treatment of TS, but the studies
are at this point small in number. There is the additional
issue in the US regarding the legal status of cannabis and
cannabis-derived pharmaceuticals, with numerous states
debating, drafting, and passing laws regarding the use of
such agents for a variety of health conditions. Large, multicenter studies are needed to truly determine the effectiveness of these medications for TS. Perhaps such studies, if
remarkably positive in treating TS, would help to shape
and move the political argument in a new direction.
Although currently limited, there are many new pathways in development that may provide unique therapeutic
choices. Unlike epilepsy, where there are numerous genetic
etiologies identified for its cause, there are precious few
genetic clues regarding the cause of TS. The first study that
has shown any statistically significant genetic results at the
population level was published earlier this year, and while
the results are important, there were genetic abnormalities
discovered in only 1% of patients with TS [85]. Deriving
therapeutic pharmaceuticals from these genetic targets does
not appear to be logical at this time.
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